DexComvs.Insulet
DXCM vs PODD · both in Diabetes & metabolic disease, part of the Medicine, pharma & life science value chain: Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring.
DexCom is about 3.4× larger than Insulet by market cap; Insulet trades at the lower P/E (27.1 vs 34.5); year to date, DexCom leads (+37.2% vs −48.8%).
Side by side
| DXCM | PODD | |
|---|---|---|
| Market cap | $34.5B | $10.2B |
| Price | $89.16 | $143.05 |
| Today | −2.1% | −1.6% |
| Return YTD | +37.2% | −48.8% |
| Return 1Y | +10.7% | −56.0% |
| P/E | 34.5 | 27.1 |
| P/S | 6.9 | 3.3 |
| P/B | 13.2 | 6.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
DexComDXCM
Continuous glucose monitoring for people with diabetes: the G-series sensors, and Stelo, which is sold over the counter.
Full DXCM profile →InsuletPODD
Maker of Omnipod, a tubeless insulin pump that handles dosing automatically.
Full PODD profile →More DXCM & PODD comparisons
Other head-to-heads in the Diabetes & metabolic disease segment.
See where DXCM and PODD sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →